Literature DB >> 19575185

Age-dependent effects of the cannabinoid CB1 antagonist SR141716A on food intake, body weight change, and pruritus in rats.

Sara Jane Ward1, Timothy W Lefever, Scott M Rawls, Garth T Whiteside, Ellen A Walker.   

Abstract

RATIONALE: The cannabinoid CB1 selective antagonist SR141716A (Rimonabant) has been shown to decrease body weight in laboratory animals and humans. Furthermore, SR141716A can elicit scratching behavior in rodents, a behavior that has been hypothesized to contribute to SR141716A-induced decrease in food intake. Although childhood obesity is a rising health issue, it is unknown whether SR141716A is equipotent at modulating food intake and other CB1-mediated behaviors in younger subjects.
OBJECTIVE: To determine whether CB1 receptor blockade is equipotent at modulating food and water intake, body weight, and scratching behavior, the effect of a range of SR141716A doses on these behaviors in food-restricted postnatal day (P) 18, 28, and 60 male rats was investigated. Brain concentrations of SR141716A were determined in each age group.
RESULTS: SR141716A dose- and age-dependently suppressed food and water intake and body weight gain and elicited head scratching, with the most potent effects observed in P18 and P28 rats. Brain concentrations of SR141716A were significantly elevated in P18 rats relative to P28 and P60 rats. SR141716A-elicited head scratching was attenuated by the 5-HT(2A/2C) antagonist ketanserin.
CONCLUSIONS: SR141716A is more potent at modulating food intake and head scratching in very young animals; these differences can be attributed to an increase in brain penetration of SR141716A for P18 but not for P28 and P60 rats. In addition, SR141716-elicited head scratching is modulated by 5HT receptor antagonism and is not a contributing factor to SR141716A's anorectic effects.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19575185     DOI: 10.1007/s00213-009-1592-6

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  36 in total

1.  RELATIONSHIP BETWEEN WATER AND FOOD INGESTION IN THE RAT.

Authors:  L J CIZEK; M R NOCENTI
Journal:  Am J Physiol       Date:  1965-04

2.  Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole--LH 21.

Authors:  Francisco Javier Pavon; Ainhoa Bilbao; Laura Hernández-Folgado; Andrea Cippitelli; Nadine Jagerovic; Gumersindo Abellán; M A Isabel Rodríguez-Franco; Antonia Serrano; Manuel Macias; Raquel Gómez; Miguel Navarro; Pilar Goya; Fernando Rodríguez de Fonseca
Journal:  Neuropharmacology       Date:  2006-06-05       Impact factor: 5.250

3.  Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin.

Authors:  Sonja Ständer; Martin Schmelz; Dieter Metze; Thomas Luger; Roman Rukwied
Journal:  J Dermatol Sci       Date:  2005-06       Impact factor: 4.563

4.  Efficacy and tolerance of the cream containing structured physiological lipids with endocannabinoids in the treatment of uremic pruritus: a preliminary study.

Authors:  Jacek C Szepietowski; Tomasz Szepietowski; Adam Reich
Journal:  Acta Dermatovenerol Croat       Date:  2005       Impact factor: 1.256

5.  Reversal of SR 141716A-induced head-twitch and ear-scratch responses in mice by delta 9-THC and other cannabinoids.

Authors:  Jano J Janoyan; Jennifer L Crim; Nissar A Darmani
Journal:  Pharmacol Biochem Behav       Date:  2002 Jan-Feb       Impact factor: 3.533

6.  Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.

Authors:  Luc F Van Gaal; Aila M Rissanen; André J Scheen; Olivier Ziegler; Stephan Rössner
Journal:  Lancet       Date:  2005 Apr 16-22       Impact factor: 79.321

7.  The ontogeny of cannabinoid receptors in the brain of postnatal and aging rats.

Authors:  R C Belue; A C Howlett; T M Westlake; D E Hutchings
Journal:  Neurotoxicol Teratol       Date:  1995 Jan-Feb       Impact factor: 3.763

8.  Involvement of other neurotransmitters in behaviors induced by the cannabinoid CB1 receptor antagonist SR 141716A in naive mice.

Authors:  N A Darmani; D K Pandya
Journal:  J Neural Transm (Vienna)       Date:  2000       Impact factor: 3.575

9.  Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study.

Authors:  André J Scheen; Nick Finer; Priscilla Hollander; Michael D Jensen; Luc F Van Gaal
Journal:  Lancet       Date:  2006-11-11       Impact factor: 79.321

10.  Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease.

Authors:  Guy W Neff; Christopher B O'Brien; K Rajender Reddy; Nora V Bergasa; Arie Regev; Enrique Molina; Rafael Amaro; Miguel J Rodriguez; VeEtta Chase; Lennox Jeffers; Eugene Schiff
Journal:  Am J Gastroenterol       Date:  2002-08       Impact factor: 10.864

View more
  5 in total

1.  A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents.

Authors:  N L Cluny; V K Vemuri; A P Chambers; C L Limebeer; H Bedard; J T Wood; B Lutz; A Zimmer; L A Parker; A Makriyannis; K A Sharkey
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

2.  CB1 receptors mediate rimonabant-induced pruritic responses in mice: investigation of locus of action.

Authors:  Joel E Schlosburg; Scott T O'Neal; Daniel H Conrad; Aron H Lichtman
Journal:  Psychopharmacology (Berl)       Date:  2011-02-22       Impact factor: 4.530

3.  Effects of morphine on pain-elicited and pain-suppressed behavior in CB1 knockout and wildtype mice.

Authors:  Laurence L Miller; Mitchell J Picker; Karl T Schmidt; Linda A Dykstra
Journal:  Psychopharmacology (Berl)       Date:  2011-03-04       Impact factor: 4.530

4.  Single and combined effects of plant-derived and synthetic cannabinoids on cognition and cannabinoid-associated withdrawal signs in mice.

Authors:  Alyssa M Myers; Patrick B Siegele; Jeffrey D Foss; Ronald F Tuma; Sara Jane Ward
Journal:  Br J Pharmacol       Date:  2018-03-01       Impact factor: 8.739

Review 5.  Cannabinoid Signaling in the Skin: Therapeutic Potential of the "C(ut)annabinoid" System.

Authors:  Kinga Fanni Tóth; Dorottya Ádám; Tamás Bíró; Attila Oláh
Journal:  Molecules       Date:  2019-03-06       Impact factor: 4.927

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.